“Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End

Daiichi Sankyo will close out its copromotion scheme with AstraZeneca K.K. (AZ) for its anti-RANKL antibody Ranmark (recombinant denosumab) on December 31, now that it believes the arrangement with the oncology powerhouse has successfully raised the drug’s profile in the...read more